Status:
UNKNOWN
Landiolol for Rate Control in Decompensated Heart Failure Due to Atrial Fibrillation
Lead Sponsor:
Institute for Clinical and Experimental Medicine
Conditions:
Atrial Fibrillation
Atrial Fibrillation Rapid
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The study will include patients with acute heart failure with reduced left ventricular ejection fraction (\<40%) triggered by atrial fibrillation (AF) with a heart rate of \>130/min. Patients in cardi...
Detailed Description
Procedure: 1. Eligible patients with signed consent will be enrolled. 2. Baseline transthoracic echocardiography, laboratory testing, evaluation of subjective dyspnea, lung water by ultrasound, chest...
Eligibility Criteria
Inclusion
- acute heart failure with reduced left ventricular ejection (\<40%)
- atrial fibrillation with heart rate \>130/min lasting presumably \>12 hours and presumably contributing to the acute heart failure
- pulmonary congestion detected by auscultation, lung ultrasound or CXR
Exclusion
- ongoing type 1. myocardial infarction
- cardiogenic shock
- presumed need for mechanical heart support during the first 48hours of the study
- presumed need for electric cardioversion during the first 2 hours of the study
- medication for heart rate control (beta-blockers, calcium channel blockers, digoxin) or antiarrhythmics introduced \<24 hours before the study. Chronic therapy with these will not be a contraindication for the study
- thyreotoxicosis
Key Trial Info
Start Date :
November 5 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04694092
Start Date
November 5 2020
End Date
December 31 2023
Last Update
January 6 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute for Clinical and Experimental Medicine (IKEM)
Prague, Czechia, 14021